Massachusetts Financial Services Co. MA Increases Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Massachusetts Financial Services Co. MA grew its holdings in Immunocore Holdings plc (NASDAQ:IMCR) by 27.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 498,221 shares of the company’s stock after buying an additional 107,656 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Immunocore were worth $15,510,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Exchange Traded Concepts LLC lifted its stake in Immunocore by 40.4% in the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after acquiring an additional 1,461 shares during the period. Connective Portfolio Management LLC purchased a new position in Immunocore during the 3rd quarter valued at $218,000. China Universal Asset Management Co. Ltd. raised its holdings in Immunocore by 69.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after purchasing an additional 3,053 shares in the last quarter. DNB Asset Management AS lifted its position in shares of Immunocore by 35.0% in the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after purchasing an additional 1,868 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Immunocore during the 2nd quarter valued at about $303,000. 84.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Needham & Company LLC decreased their price objective on Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Oppenheimer reiterated an “outperform” rating and set a $89.00 target price (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. Guggenheim downgraded Immunocore from a “buy” rating to a “neutral” rating in a research note on Monday, October 7th. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Thursday, October 24th. Finally, Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $69.18.

Immunocore Stock Performance

Shares of IMCR stock opened at $32.79 on Tuesday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The company has a 50 day moving average price of $32.30 and a 200-day moving average price of $37.17. Immunocore Holdings plc has a 52 week low of $29.72 and a 52 week high of $76.98. The firm has a market capitalization of $1.64 billion, a PE ratio of -34.52 and a beta of 0.72.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million during the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm’s revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.59) EPS. As a group, equities research analysts expect that Immunocore Holdings plc will post -0.94 earnings per share for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.